Ligand Pharmaceuticals LGND Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Ligand Pharmaceuticals (LGND) reported accretion (amortization) of discounts and premiums, investments of $1.5M in Q1 2026.
- How has Ligand Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Ligand Pharmaceuticals's accretion (amortization) of discounts and premiums, investments increased by 79.0% year-over-year, from $839K to $1.5M.
- What is the long-term trend for Ligand Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 94.0% compound annual growth rate (CAGR), from $1.32M to $4.96M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric captures the non-cash adjustment to the carrying value of debt or investment securities to reflect the amortization of premiums or the accretion of discounts over time. It aligns the effective interest rate of financial instruments with their stated coupon rates. This adjustment is essential for reconciling net income to actual cash flows generated by financing and investment activities.